COMP <GO>
USNA vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
USANA Health Sciences Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: USNA 3
— LLY 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $14.34 (-1.91%) • MKT CAP: $265.0M
balance-sheet
3.56
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USNA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USNA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.30% | 83.64% | -5.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 32.36% | -24.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 2.7x | 36.4x | -33.72 | USNA | /valuation <GO> |
| Free Cash Flow Yield | 3.22% | 2.30% | +0.92 | USNA | /fcf-yield <GO> |
| Operating Margin | 4.00% | 40.21% | -36.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 1.20% | 31.90% | -30.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 45.51% | -37.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.56 | 9.29 | -5.73 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 66.6 | -21.31 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.9x | 26.3x | -3.35 | USNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $265.0M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USNA REV | LLY REV | USNA GROSS % | LLY GROSS % | USNA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $925.3M | $65.18B | 78.3% | 83.0% | $8.5M | $16.81B |
| FY 2024 | $854.5M | $45.04B | 81.1% | 81.3% | $50.9M | $8.82B |
| FY 2023 | $921.0M | $34.12B | — | 79.3% | $70.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USNA // BETA —
LLY // BETA 0.51